3058592-88-1
Chemical Structure
Zocilurtatug pelitecan
Synonym(s): ZL-1310
- CAS No.: 3058592-88-1
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Zocilurtatug pelitecan]
Biological Activity: Zocilurtatug pelitecan (ZL-1310) is a blood-brain barrier-penetrating antibody-drug conjugate targeting DLL3. It consists of the antibody component Zocilurtatug (HY-P992148) and the toxin-linker molecule DL-01 (HY-155870). Zocilurtatug pelitecan induces cell cycle arrest and apoptosis in tumor cells, and inhibits the growth of established human tumors in xenograft models. It can be used in research on extensive-stage small cell lung cancer (SCLC) and neuroendocrine tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zocilurtatug pelitecan | Zocilurtatug pelitecan (ZL-1310) is a blood-brain barrier-penetrating antibody-drug conjugate targeting DLL3. It consists of the antibody component Zocilurtatug (HY-P992148) and the toxin-linker molecule DL-01 (HY-155870). Zocilurtatug pelitecan induces cell cycle arrest and apoptosis in tumor cells, and inhibits the growth of established human tumors in xenograft models. It can be used in research on extensive-stage small cell lung cancer (SCLC) and neuroendocrine tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Lin, L. N., et al. (2024). 241P Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors. ESMo Open, 9.
-
[2]. Dowlati, A., et al. (2026). A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).
Keywords
